NCT02439216View on ClinicalTrials.gov

Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

January 12, 2017

Study Completion Date

August 31, 2019

Conditions
Muscular Dystrophy, Duchenne
Interventions
DRUG

Edasalonexent

DRUG

Placebo

Trial Locations (5)

19104

Philadelphia

32610

Gainesville

32827

Orlando

90095

Los Angeles

97239

Portland

Sponsors
All Listed Sponsors
lead

Catabasis Pharmaceuticals

INDUSTRY

NCT02439216 - Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter